The impact of peginterferon alpha-2a maintenance therapy on portal hypertension in patients with chronic hepatitis C virus infection and advanced fibrosis and cirrhosis enrolled in the HALT-C trial
Phase of Trial: Phase II/III
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis C; Portal hypertension
- Focus Therapeutic Use
- 18 Dec 2007 Status changed from recruiting to completed.
- 23 Feb 2006 New trial record.